CN116323939A - 病毒不易感动物及其构建方法 - Google Patents
病毒不易感动物及其构建方法 Download PDFInfo
- Publication number
- CN116323939A CN116323939A CN202180060541.1A CN202180060541A CN116323939A CN 116323939 A CN116323939 A CN 116323939A CN 202180060541 A CN202180060541 A CN 202180060541A CN 116323939 A CN116323939 A CN 116323939A
- Authority
- CN
- China
- Prior art keywords
- gene
- grna
- virus
- animal
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 157
- 238000010276 construction Methods 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 255
- 238000000034 method Methods 0.000 claims abstract description 82
- 108090000141 Sialyltransferases Proteins 0.000 claims abstract description 40
- 102000003838 Sialyltransferases Human genes 0.000 claims abstract description 40
- 108020005004 Guide RNA Proteins 0.000 claims description 158
- 210000004027 cell Anatomy 0.000 claims description 91
- 150000007523 nucleic acids Chemical group 0.000 claims description 82
- 239000013598 vector Substances 0.000 claims description 66
- 241000712461 unidentified influenza virus Species 0.000 claims description 64
- 108091033409 CRISPR Proteins 0.000 claims description 56
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 46
- 238000000338 in vitro Methods 0.000 claims description 30
- 238000013518 transcription Methods 0.000 claims description 30
- 230000035897 transcription Effects 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 28
- 102000053602 DNA Human genes 0.000 claims description 27
- 241000700605 Viruses Species 0.000 claims description 27
- 230000008685 targeting Effects 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 25
- 206010022000 influenza Diseases 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 108700024394 Exon Proteins 0.000 claims description 17
- 101710163270 Nuclease Proteins 0.000 claims description 17
- 238000010354 CRISPR gene editing Methods 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 102000018697 Membrane Proteins Human genes 0.000 claims description 11
- 108010052285 Membrane Proteins Proteins 0.000 claims description 11
- 230000005782 double-strand break Effects 0.000 claims description 11
- 230000005783 single-strand break Effects 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 9
- 244000144972 livestock Species 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 108010042407 Endonucleases Proteins 0.000 claims description 7
- 102000004533 Endonucleases Human genes 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 210000004602 germ cell Anatomy 0.000 claims description 7
- 210000003101 oviduct Anatomy 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 238000010362 genome editing Methods 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 108700026220 vif Genes Proteins 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 230000002906 microbiologic effect Effects 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 238000012356 Product development Methods 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000009027 insemination Effects 0.000 claims description 3
- 230000013011 mating Effects 0.000 claims description 3
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 2
- 230000014639 sexual reproduction Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000009877 rendering Methods 0.000 abstract description 5
- 102000005962 receptors Human genes 0.000 description 73
- 108020003175 receptors Proteins 0.000 description 73
- 241000282898 Sus scrofa Species 0.000 description 72
- 241000282887 Suidae Species 0.000 description 36
- 238000003209 gene knockout Methods 0.000 description 31
- 239000000047 product Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 210000000287 oocyte Anatomy 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 210000000801 secondary oocyte Anatomy 0.000 description 9
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 108091028113 Trans-activating crRNA Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- -1 caslB Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000194020 Streptococcus thermophilus Species 0.000 description 4
- 101150073130 ampR gene Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 101150038500 cas9 gene Proteins 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002219 extraembryonic membrane Anatomy 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000007026 protein scission Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 101710136191 Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 101150017047 CSM3 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 101150078885 CSY3 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100275895 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) csnB gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101100007792 Escherichia coli (strain K12) casB gene Proteins 0.000 description 1
- 101100219622 Escherichia coli (strain K12) casC gene Proteins 0.000 description 1
- 101100382541 Escherichia coli (strain K12) casD gene Proteins 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 101100005249 Escherichia coli (strain K12) ygcB gene Proteins 0.000 description 1
- 101150106478 GPS1 gene Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000029812 HNH nuclease Human genes 0.000 description 1
- 108060003760 HNH nuclease Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101100494762 Mus musculus Nedd9 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 101100387128 Myxococcus xanthus (strain DK1622) devR gene Proteins 0.000 description 1
- 101100387131 Myxococcus xanthus (strain DK1622) devS gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 241001313536 Thermothelomyces thermophila Species 0.000 description 1
- 101100273269 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) cse3 gene Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 1
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 101150055191 cas3 gene Proteins 0.000 description 1
- 101150111685 cas4 gene Proteins 0.000 description 1
- 101150049463 cas5 gene Proteins 0.000 description 1
- 101150106467 cas6 gene Proteins 0.000 description 1
- 101150044165 cas7 gene Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 101150100788 cmr3 gene Proteins 0.000 description 1
- 101150040342 cmr4 gene Proteins 0.000 description 1
- 101150095330 cmr5 gene Proteins 0.000 description 1
- 101150034961 cmr6 gene Proteins 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 101150085344 csa5 gene Proteins 0.000 description 1
- 101150088639 csm4 gene Proteins 0.000 description 1
- 101150022488 csm5 gene Proteins 0.000 description 1
- 101150064365 csm6 gene Proteins 0.000 description 1
- 101150016576 csy2 gene Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011819 knockout animal model Methods 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
物种 | 基因名称 | GenBank Gene ID |
猪 | ST3Gal4 | 396602 |
猪 | ST6Gal1 | 100302026 |
Claims (66)
- 一种构建病毒不易感动物的方法,所述方法包括敲除动物中编码唾液酸转移酶的基因的全部或部分,从而使所述动物成为病毒不易感的动物。
- 根据权利要求1所述的方法,其中所述编码唾液酸转移酶的基因包括ST3Gal4基因、ST6Gal1基因、ST3Gal3基因和/或ST3Gal6基因。
- 根据权利要求1-2中任一项所述的方法,其中所述唾液酸转移酶包括2,3-半乳糖唾液酸寡糖(SAα2,3Gal)受体,和/或2,6-半乳糖唾液酸寡糖(SAα2,6Gal)受体。
- 根据权利要求3所述的方法,其中所述编码2,3-半乳糖唾液酸寡糖(SAα2,3Gal)受体的基因包括ST3Gal4基因。
- 根据权利要求3-4中任一项所述的方法,其中所述编码2,6-半乳糖唾液酸寡糖(SAα2,6Gal)受体的基因包括ST6Gal1基因。
- 根据权利要求1-5中任一项所述的方法,其中所述动物包括家畜。
- 根据权利要求1-6中任一项所述的方法,其中所述动物包括猪科动物。
- 根据权利要求1-7中任一项所述的方法,其中所述敲除包括在所述编码唾液酸转移酶的基因中添加、替换和/或删除一个或多个核苷酸,使所述编码唾液酸转移酶的基因的表达量降低,和/或,使所述编码唾液酸转移酶的基因基本上不表达;和/或,使所述唾液酸转移酶的氨基酸序列改变,和/或,使所述唾液酸转移酶失活。
- 根据权利要求5-8中任一项所述的方法,其中所述敲除包括在所述ST3Gal4基因和/或所述ST6Gal1基因中添加、替换和/或删除一个或多个核苷酸,使所述ST3Gal4基因和/或所述ST6Gal1基因的表达量降低,和/或,使所述ST3Gal4基因和/或所述ST6Gal1基因基本上不表达;和/或,使所述SAα2,3Gal受体和/或所述SAα2,3Gal受体的氨基酸序列改变,和/或,使所述SAα2,3Gal受体和/或所述SAα2,3Gal受体失活。
- 根据权利要求4-9中任一项所述的方法,其中所述敲除涉及敲除所述ST3Gal4基因的2个或多个外显子的全部或部分。
- 根据权利要求5-10中任一项所述的方法,其中所述敲除涉及敲除所述ST6Gal1基因的1个或多个外显子的全部或部分。
- 根据权利要求4-11中任一项所述的方法,其中所述方法包括以下的步骤:使用一种或多种脱氧核糖核酸(DNA)核酸内切酶以在所述ST3Gal4基因和/或所述ST6Gal1基因内或其附近产生一个或更多个单链断裂(SSB)或双链断裂(DSB),从而使得所述ST3Gal4基因和/或所述ST6Gal1基因的一个或更多个外显子全部或部分缺失。
- 根据权利要求12所述的方法,其中所述DNA内切酶包括Cas核酸酶。
- 根据权利要求13所述的方法,其中所述Cas核酸酶包括Cas9核酸酶、其同源物、其天然存在分子的重组体、其密码子优化版本,和/或其经修饰版本。
- 根据权利要求1-14中任一项所述的方法,其中所述方法还包括使用一种或多种向导RNA(gRNA)。
- 根据权利要求15所述的方法,其中所述gRNA为单链向导RNA(sgRNA)。
- 根据权利要求15-16中任一项所述的方法,其中所述gRNA能够特异性结合所述ST3Gal4基因中包含SEQ ID NO:5-6和20中任一项所示核酸序列的靶区域。
- 根据权利要求15-17中任一项所述的方法,其中能够特异性结合所述ST3Gal4基因的所述gRNA包含SEQ ID NO:9-10和21-22中任一项所示核酸序列。
- 根据权利要求15-18中任一项所述的方法,其中所述gRNA能够特异性结合所述ST6Gal1基因中包含SEQ ID NO:7-8中任一项所示核酸序列的靶区域。
- 根据权利要求15-19中任一项所述的方法,其中能够特异性结合所述ST6Gal1基因的所述gRNA包含SEQ ID NO:11-12和23-24中任一项所示核酸序列。
- 根据权利要求15-20中任一项所述的方法,其中所述gRNA的5’端包括(X)n所示的核酸序列,其中所述中X为选自A、U、C和G中任一个的碱基,且n为0-15中的任一整数。
- 根据权利要求21所述的方法,其中所述n为13或2。
- 根据权利要求15-22中任一项所述的方法,其中所述gRNA的3’端包括骨架序列。
- 根据权利要求1-23中任一项所述的方法,其中所述方法包括:(1)提供一种细胞,所述细胞包含一种或多种包含所述gRNA的载体或所述载体的体外转录产物;(2)将所述细胞在培养液中进行培养;(3)将培养后的细胞移植至受体雌性非人哺乳动物的输卵管内,允许所述细胞在所述雌性非人哺乳动物的子宫中发育;和(4)鉴定步骤(3)的怀孕雌性的后代基因改造的非人哺乳动物中的种系传递。
- 根据权利要求1-24中任一项所述的方法,其中所述病毒包括流感病毒。
- 根据权利要求25所述的方法,其中所述流感病毒包括人流感病毒和/或禽流感病毒。
- 根据权利要求3-26中任一项所述的方法,其中所述病毒不易感动物基本上不表达能够与所述病毒的表面蛋白相互作用的内源性的所述SAα2,3Gal受体和/或所述SAα2,6Gal受体。
- 根据权利要求3-27中任一项所述的方法,其中所述病毒不易感动物基本上不表达内源性的所述SAα2,3Gal受体和/或所述SAα2,6Gal受体。
- 一种特异性结合ST3Gal4基因的gRNA,其中所述gRNA特异性结合包含SEQ ID NO:5-6和20中任一项所示核酸序列的靶区域。
- 根据权利要求29所述的gRNA,其靶向所述ST3Gal4基因中2个以上不同的外显子。
- 根据权利要求29-30中任一项所述的gRNA,其包含SEQ ID NO:9-10和21-22中任一项所示核酸序列。
- 一种特异性结合ST6Gal1基因的gRNA,其中所述gRNA特异性结合包含SEQ ID NO:7-8中任一项所示核酸序列的靶区域。
- 根据权利要求32所述的gRNA,其靶向所述ST6Gal1基因中1个外显子。
- 根据权利要求32-33中任一项所述的gRNA,其包含SEQ ID NO:11-12和23-24中任一项所示核酸序列。
- 根据权利要求29-34中任一项所述的gRNA,其中所述gRNA为单链向导RNA(sgRNA)。
- 根据权利要求29-35中任一项所述的gRNA,其中所述gRNA的5’端包括(X)n所示的核酸序列,其中所述中X为选自A、U、C和G中任一个的碱基,且n为0-15中的任一整数。
- 根据权利要求36所述的gRNA,其中所述n为13或2。
- 根据权利要求29-37中任一项所述的gRNA,其中所述gRNA的3’端包括骨架序列。
- 核酸分子,其编码权利要求29-38中任一项所述的gRNA。
- 包含权利要求29-38中任一项所述的gRNA的序列的载体。
- 一种细胞,其包含一种或多种权利要求29-38中任一项所述的gRNA,权利要求39所述的核酸分子,权利要求40所述的gRNA载体,和/或权利要求40所述的gRNA载体的体外转录产物。
- 权利要求29-38中任一项所述的gRNA,权利要求39所述的核酸分子,权利要求40所述的gRNA载体,和/或权利要求40所述的gRNA载体的体外转录产物,和/或权利要求41所述的细胞在敲除ST3Gal4基因和/或ST6Gal1基因中的用途,或在构建病毒不易感动物中的用途。
- 一种ST3Gal4基因缺失细胞株,其是使用权利要求29-31中任一项所述的gRNA,权利要求39所述的核酸分子,权利要求40所述的gRNA载体,和/或权利要求40所述的gRNA载体的体外转录产物,和/或权利要求41所述的细胞制备获得的。
- 根据权利要求1-28中任一所述的方法制备获得的病毒不易感动物,其中所述病毒不易感动物基本上不表达能够与病毒表面蛋白相互作用的内源性SAα2,3Gal受体。
- 根据权利要求1-28中任一所述的方法制备获得的病毒不易感动物,其中所述病毒不易感 动物基本上不表达内源性SAα2,3Gal受体。
- 一种ST6Gal1基因缺失细胞株,其是使用权利要求32-34中任一项所述的gRNA,权利要求39所述的核酸分子,权利要求40所述的gRNA载体,权利要求40所述的gRNA载体的体外转录产物,和/或权利要求41所述的细胞制备获得的。
- 根据权利要求1-28中任一所述的方法制备获得的病毒不易感动物,其中所述病毒不易感动物基本上不表达能够与病毒表面蛋白相互作用的内源性SAα2,6Gal受体。
- 根据权利要求1-28中任一所述的方法制备获得的病毒不易感动物,其中所述病毒不易感动物基本上不表达内源性SAα2,6Gal受体。
- 一种制备病毒不易感动物的方法,所述方法包括:(a)提供权利要求1-28中任一项所述的方法制备获得的病毒不易感动物;以及(b)将步骤(a)获得的病毒不易感动物与其它动物交配或体外授精或对基于步骤(a)获得的病毒不易感动物进一步进行基因编辑或将人组织、细胞移植至步骤(a)获得的病毒不易感动物中,并进行筛选,得到病毒不易感动物。
- 根据权利要求49所述的方法,其中所述方法包括:将权利要求44-45中任一项所述的基本上不表达内源性SAα2,3Gal受体的病毒不易感动物与权利要求47-48中任一项所述的基本上不表达内源性SAα2,6Gal受体的病毒不易感动物有性繁殖。
- 根据权利要求50所述的方法,其中所述方法包括:所述杂交后筛选基本上不表达所述内源性SAα2,3Gal受体且不基本上不表达所述内源性SAα2,6Gal受体的动物,得到病毒不易感动物。
- 根据权利要求49-51中任一项所述的方法制备获得的病毒不易感动物。
- 根据权利要求52所述的病毒不易感动物,其包括家畜。
- 根据权利要求52-53中任一项所述的病毒不易感动物,其包括猪科动物。
- 根据权利要求52-54中任一项所述的病毒不易感动物,其中所述病毒包括流感病毒。
- 根据权利要求55所述的病毒不易感动物,其中所述流感病毒包括人流感病毒和/或禽流感病毒。
- 一种细胞或细胞系或原代细胞培养物,其中所述的细胞或细胞系或原代细胞培养物来源于权利要求52-56中任一项所述的病毒不易感动物或者其后代。
- 一种组织或器官或其培养物,其中所述组织或器官或其培养物来源于权利要求52-56中任一项所述的病毒不易感动物或者其后代。
- 一种特异靶向敲除ST3Gal4基因的CRISPR/Cas9系统,其使用含有权利要求29-31中任一项所述的能够特异的靶向ST3Gal4基因的gRNA的DNA序列。
- 一种能够特异性靶向ST3Gal4基因的核酸分子试剂盒,其中,所述试剂盒包括权利要求29-31中任一所述的gRNA。
- 一种能够特异的靶向ST3Gal4基因的成套核酸分子,其中,所述成套核酸分子包括权利要求29-31中任一项所述的gRNA和编码Cas9蛋白的核酸分子。
- 一种特异靶向敲除ST6Gal1基因的CRISPR/Cas9系统,其特征在于,使用含有权利要求32-34中任一项所述的能够特异的靶向ST6Gal1基因的gRNA的DNA序列。
- 一种能够特异性靶向ST6Gal1基因的核酸分子试剂盒,其中,所述试剂盒包括权利要求32-34中任一所述的gRNA。
- 一种能够特异的靶向ST6Gal1基因的成套核酸分子,其中,所述成套核酸分子包括权利要求32-34中任一项所述的gRNA和编码Cas9蛋白的核酸分子。
- 权利要求44-45、47-48和52-56中任一项所述的病毒不易感动物在抗病毒产品开发,或者作为药理学、免疫学、微生物学和医学研究的模型系统中的应用。
- 权利要求44-45、47-48和52-56中任一项所述的病毒不易感动物在筛选、验证、评价或研究抗病毒药物或组合药物、和/或药效研究方面的应用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020106926502 | 2020-07-17 | ||
CN202010692650 | 2020-07-17 | ||
PCT/CN2021/106740 WO2022012663A1 (zh) | 2020-07-17 | 2021-07-16 | 病毒不易感动物及其构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116323939A true CN116323939A (zh) | 2023-06-23 |
Family
ID=79554486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180060541.1A Pending CN116323939A (zh) | 2020-07-17 | 2021-07-16 | 病毒不易感动物及其构建方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116323939A (zh) |
WO (1) | WO2022012663A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103667285B (zh) * | 2012-09-12 | 2015-09-09 | 广州呼吸疾病研究所 | 可防治流感的siRNA及其药物组合物、医药用途 |
ES2797050T3 (es) * | 2014-03-04 | 2020-12-01 | Sigma Aldrich Co Llc | Células virales resistentes y sus usos |
CN110564772B (zh) * | 2019-04-03 | 2022-07-05 | 安泰吉(北京)生物技术有限公司 | 改造宿主细胞基因组的方法及其用途 |
-
2021
- 2021-07-16 CN CN202180060541.1A patent/CN116323939A/zh active Pending
- 2021-07-16 WO PCT/CN2021/106740 patent/WO2022012663A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022012663A1 (zh) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6878482B2 (ja) | 大型家畜の接合体における標的化ゲノム編集 | |
CN108660161B (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
US20230189769A1 (en) | Process for using crispr to transfect primordial germ cells in avians | |
Zhang et al. | Disruption of the sheep BMPR-IB gene by CRISPR/Cas9 in in vitro-produced embryos | |
CN111647627A (zh) | 多重基因编辑 | |
CN106417184A (zh) | 经遗传修饰的动物及其生成方法 | |
US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
JP2018531003A6 (ja) | 向上した耐暑性を有する遺伝子改変動物 | |
US20230272397A1 (en) | Methods for improving the health of porcine species by targeted inactivation of cd163 | |
US20210037797A1 (en) | Inducible disease models methods of making them and use in tissue complementation | |
WO2022012512A1 (zh) | 敲除猪异种抗原的基因的gRNA及其应用 | |
WO2022012663A1 (zh) | 病毒不易感动物及其构建方法 | |
Sasaki | Development of genetically modified nonhuman primates toward models for translational research | |
Yang et al. | Production of CFTR-F508 Rabbits | |
CN117363649A (zh) | 基因整合方法及应用 | |
CN115948477A (zh) | 一种提高CRISPR/Cas9的同源重组修复效率的诱导剂、方法以及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240115 Address after: Lv Zhihe Building, School of Life Sciences, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing, 100871 Applicant after: Rao Yi Address before: B7-101, No. 218 Xinghu Street, Industrial Park, Suzhou City, Jiangsu Province, 215000 Applicant before: Chuangguan (Suzhou) Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40095683 Country of ref document: HK |